Michael Shuler,
Samuel B. Eckert Professor of Engineering,
Cornell University, President Hesperos, Inc.
Michael L. Shuler is the Eckert Professor of Engineering, Emeritus in the Meing Department of Biomedical Engineering and in the Smith School of Chemical and Biomolecular Engineering at Cornell University, and was director of Cornell’s Nanobiotechnology Center. Shuler has degrees in chemical engineering (BS, Notre Dame, 1969 and Ph.D., Minnesota, 1973) and has been a faculty member at Cornell University since 1974. Shuler’s research includes development of “Body-on-a-Chip” for testing pharmaceuticals for toxicity and efficacy, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and construction of whole cell models relating genome to physiology. Shuler is CEO and President of Hesperos, a company founded to implement the “Body-on-a-Chip” system. Shuler and F. Kangi have authored a popular textbook, “Bioprocess Engineering; Basic Concepts” now in its third edition. He has an honorary doctorate from the University of Notre Dame. Shuler has been elected to the National Academy of Engineering and the American Academy of Arts and Science and is a fellow of numerous professional societies.
Body on a Chip: A Transformative Approach to Improve Drug Development
Monday, 22 March 2021 at 11:00
Add to Calendar ▼2021-03-22 00:00:002021-03-22 01:00:00Europe/LondonTitle to be Confirmed.3D-Culture, Organoids and Organs-on-Chips 2021 in SELECTBIOenquiries@selectbiosciences.com
A physiologically representative, multi-organ microphysiological systems
(MPS) based on human tissues (also known as “human-on-a-chip” TM) may
be a transformative technology to improve the selection of drug
candidates most likely to earn regulatory approval from clinical trials.
Such microscale systems combine organized human tissues with the
techniques of microfabrication based on PBPK (Physiologically Based
Pharmacokinetic) models.
I will describe such systems being
constructed at Hesperos and at Cornell. They are “self-contained” in
that they can operate independently and do not require external pumps as
is the case with many other microphysiological systems. They are “low
cost”, in part, because of the simplicity and reliability of operation.
They maintain a ratio of fluid (blood surrogate) to cells that is more
physiologic than in many other in vitro systems allowing the observation
of the effects of not only drugs but their metabolites. While systems
can be sampled to measure the concentrations of drugs, metabolites, or
biomarkers, they also can be interrogated in situ for functional
responses such as electrical activity, force generation, or integrity of
barrier function. Operation up to 28 days has been achieved allowing
observation of both acute and chronic responses with serum free media.
Add to Calendar ▼2021-03-22 00:00:002021-03-23 00:00:00Europe/London3D-Culture, Organoids and Organs-on-Chips 20213D-Culture, Organoids and Organs-on-Chips 2021 in SELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2021-03-22 00:00:002021-03-22 01:00:00Europe/LondonTitle to be Confirmed.3D-Culture, Organoids and Organs-on-Chips 2021 in SELECTBIOenquiries@selectbiosciences.com
